{"id":551028,"date":"2021-07-02T17:12:01","date_gmt":"2021-07-02T17:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551028"},"modified":"2021-07-02T17:12:01","modified_gmt":"2021-07-02T17:12:01","slug":"duchenne-muscular-dystrophy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551028.html","title":{"rendered":"Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625204156.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625204156.png\" alt=\"Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cDuchenne Muscular Dystrophy Pipeline Insight\u201d report provides comprehensive insights about keycompanies and pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscapes. It comprises Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and non-clinical stage products. <\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&rsquo;s <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">&ldquo;<\/span><strong><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Pipeline Insight<\/span><\/strong><span data-mce-mark=\"1\">&rdquo;<\/span><\/a><span data-mce-mark=\"1\"> report provides comprehensive insights about key companies<\/span><span data-mce-mark=\"1\">&nbsp;and pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscapes. It comprises Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Duchenne Muscular Dystrophy pipeline products.&nbsp; &nbsp; &nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span>Some of the key takeaways of the <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span>Duchenne Muscular Dystrophy Pipeline Report<\/span><\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as <\/span><span data-mce-mark=\"1\">Italfarmaco, <\/span><span data-mce-mark=\"1\">Catabasis Pharmaceuticals, Santhera Pharmaceuticals, <\/span><span data-mce-mark=\"1\">Hoffmann-La Roche, FibroGen, <\/span><span data-mce-mark=\"1\">Capricor, Antisense Therapeutics, ReveraGen BioPharma,&nbsp;<\/span><span data-mce-mark=\"1\">etc., are developing therapies for the treatment of Duchenne Muscular Dystrophy.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such <\/span><span data-mce-mark=\"1\">as <\/span><span data-mce-mark=\"1\">Givinostat, Edasalonexent, Idebenone, RG6206 (BMS-986089), Pamrevlumab, CAP-1002, ATL1102, and Vamorolone, <\/span><span data-mce-mark=\"1\">are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Duchenne Muscular Dystrophy <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span data-mce-mark=\"1\">Get an overview of pipeline landscape @ <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Clinical Trials Analysis&nbsp;<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called <\/span><span data-mce-mark=\"1\">dystrophin <\/span><span data-mce-mark=\"1\">that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Emerging Drugs<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Givinostat <\/strong>by <strong>Italfarmaco&nbsp;<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong>Edasalonexent <\/strong>by<strong> Catabasis Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong>Idebenone <\/strong>by <strong>Santhera Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong>RG6206 (BMS-986089) <\/strong>by <strong>Hoffmann-La Roche<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span>Scope of <\/span><span>Duchenne Muscular Dystrophy Pipeline Drug Insight<\/span><span>&nbsp; &nbsp;<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage: <\/span><span data-mce-mark=\"1\">Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:<\/span><span data-mce-mark=\"1\"> Italfarmaco, <\/span><span data-mce-mark=\"1\">Catabasis Pharmaceuticals, Santhera Pharmaceuticals, <\/span><span data-mce-mark=\"1\">Hoffmann-La Roche, FibroGen, <\/span><span data-mce-mark=\"1\">Capricor, Antisense Therapeutics, ReveraGen BioPharma, <\/span><span data-mce-mark=\"1\">and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\"> Givinostat, Edasalonexent, Idebenone, RG6206 (BMS-986089), Pamrevlumab, CAP-1002, ATL1102, Vamorolone, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Table of Contents<\/span><\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Related Reports:<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Market&nbsp;<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Duchenne Muscular Dystrophy &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-epidemiology-forecast-report?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">Duchenne Muscular Dystrophy Epidemiology<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Duchenne Muscular Dystrophy &#8211; Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">About <\/span><span data-mce-mark=\"1\">DelveInsight<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers <\/span><span>Healthcare Consulting Services<\/span><span>, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=duchenne-muscular-dystrophy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=duchenne-muscular-dystrophy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cDuchenne Muscular Dystrophy Pipeline Insight\u201d report provides comprehensive insights about keycompanies and pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscapes. It comprises Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and non-clinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/duchenne-muscular-dystrophy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551028.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-551028","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551028"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}